无免费午餐:急性淋巴细胞白血病新型免疫治疗毒性的管理,包括经济毒性
该综述聚焦急性淋巴细胞白血病(ALL)新型免疫治疗相关毒性,包括inotuzumab的肝窦阻塞综合征、blinatumomab的细胞因子释放综合征(CRS)与神经毒性、CAR-T更常见且更严重的CRS与神经毒性,以及这些药物的经济负担与成本效益数据。
要点
- inotuzumab(CD22抗体药物偶联物)相关肝窦阻塞综合征若伴多器官衰竭,可致死率>80%。
- blinatumomab(CD19单克隆抗体)相关CRS和神经毒性需及时识别,主要用糖皮质激素管理。
- CAR-T相关CRS和神经毒性更常见且更严重,且CAR-T无法按需停用增加了毒性管理复杂性。
核心结论
- ALL新型免疫治疗毒性包括医学毒性和经济毒性,需了解预期、识别和管理这些毒性。
- 多数研究的中位随访有限,长期缓解持久性数据仍需观察。
研究设计与样本
- 综述,聚焦ALL新型免疫治疗相关毒性及其管理,并回顾这些药物成本效益的现有数据。
主要发现
- inotuzumab相关肝窦阻塞综合征若伴多器官衰竭,可致死率>80%。
- blinatumomab相关CRS和神经毒性需及时识别,主要用糖皮质激素管理。
- CAR-T相关CRS和神经毒性更常见且更严重,且CAR-T无法按需停用增加毒性管理复杂性。
- 托珠单抗(IL-6受体阻滞剂)用于治疗CAR-T所致严重CRS,糖皮质激素仍是神经毒性管理的主要手段。
- 这些药物虽有效但价格高昂,现有成本效益数据的中位随访有限,长期缓解持久性数据仍需观察。
关键数值与推荐
- inotuzumab相关肝窦阻塞综合征伴多器官衰竭时,可致死率>80%。
- 托珠单抗用于治疗CAR-T所致严重CRS;糖皮质激素仍是神经毒性管理的主要手段。
临床怎么用
- 作者提醒读者了解新型免疫治疗的预期毒性、识别方法和管理策略。
- CRS和神经毒性需及时识别,主要用糖皮质激素管理;托珠单抗用于治疗CAR-T所致严重CRS。
局限性
- 多数研究的中位随访有限。
- 长期缓解持久性数据仍需观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic options for acute lymphoblastic leukemia, especially in the relapsed/refractory setting, have expanded significantly in recent times. However, this comes at the cost of toxicities: medical as well as financial. We highlight some of the unique toxicities associated with the novel agents to apprise our readers about what to expect, how to recognize them, and how to manage these toxicities. One of the toxicities seen with inotuzumab, a CD22 antibody drug conjugate, is sinusoidal obstruction syndrome, which can be fatal in >80% of patients if associated with multiorgan failure. Blinatumomab, a monoclonal antibody targeting CD19, is associated with cytokine release syndrome (CRS) and neurotoxicity, both of which require prompt recognition and management primarily with corticosteroids. CRS and neurotoxicity are more common and more severe with chimeric antigen receptor T-cell therapy (CAR-T). The fact that CAR-T cannot be discontinued on demand adds a layer of complexity to the management of related toxicities of this therapy. Tocilizumab, an interleukin-6 receptor blocker, is used to treat severe CRS from CAR-T, whereas corticosteroids remain the mainstay for neurotoxicity management. Although effective, these drugs carry a high price tag, and we review the available data on cost-effectiveness of these agents, keeping in mind that median follow-up on most of these studies is limited and that long-term data on durability of response remain to be seen.
引用
- Jain T, Litzow MR. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv. 2018. PMID: 30482769. doi:10.1182/bloodadvances.2018020198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。